Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
22
12
2022
accepted:
25
04
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Despite the recent introduction of next-generation immunotherapeutic agents, multiple myeloma (MM) remains incurable. New strategies targeting MM-specific antigens may result in a more effective therapy by preventing antigen escape, clonal evolution, and tumor resistance. In this work, we adapted an algorithm that integrates proteomic and transcriptomic results of myeloma cells to identify new antigens and possible antigen combinations. We performed cell surface proteomics on 6 myeloma cell lines based and combined these results with gene expression studies. Our algorithm identified 209 overexpressed surface proteins from which 23 proteins could be selected for combinatorial pairing. Flow cytometry analysis of 20 primary samples confirmed the expression of FCRL5, BCMA, and ICAM2 in all samples and IL6R, endothelin receptor B (ET
Identifiants
pubmed: 37359190
doi: 10.1097/HS9.0000000000000901
pmc: PMC10289631
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e901Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Déclaration de conflit d'intérêts
DB and AH are scientific cofounders and hold equity in Skymab Biotherapeutics. All the other authors have no conflicts of interest to disclose.
Références
MAbs. 2013 Jan-Feb;5(1):56-69
pubmed: 23221682
Sci Rep. 2022 Feb 23;12(1):3069
pubmed: 35197510
Cancers (Basel). 2021 Dec 06;13(23):
pubmed: 34885245
Nat Rev Cancer. 2013 Sep;13(9):637-51
pubmed: 23884378
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Cancer Treat Res Commun. 2021;29:100494
pubmed: 34837796
Blood. 2006 Sep 15;108(6):2020-8
pubmed: 16728703
Nat Commun. 2021 Feb 8;12(1):868
pubmed: 33558511
Front Oncol. 2021 Jan 08;10:600025
pubmed: 33489901
Nat Immunol. 2021 Jun;22(6):769-780
pubmed: 34017122
Talanta. 2020 Jun 1;213:120812
pubmed: 32200919
Br J Haematol. 2019 Mar;184(6):1052-1055
pubmed: 29726006
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
J Hematol Oncol. 2022 Feb 16;15(1):17
pubmed: 35172851
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32771993
Blood Cancer J. 2021 Nov 11;11(11):178
pubmed: 34764237
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Blood Cancer J. 2022 Jan 26;12(1):15
pubmed: 35082295
Br J Haematol. 2017 Sep;178(5):781-793
pubmed: 28597546
Nat Commun. 2019 Nov 26;10(1):5387
pubmed: 31772172
Sci Rep. 2017 Aug 23;7(1):9257
pubmed: 28835615
Nat Med. 2017 Dec;23(12):1436-1443
pubmed: 29106400
J Hematol Oncol. 2020 Jun 22;13(1):82
pubmed: 32571377
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Physiol Res. 2018 Jun 27;67(Suppl 1):S257-S264
pubmed: 29947545
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Blood. 2022 Apr 21;139(16):2471-2482
pubmed: 35134130
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Nat Biotechnol. 2013 Jan;31(1):71-5
pubmed: 23242161
Front Immunol. 2020 May 07;11:762
pubmed: 32457743
Nat Med. 2021 Apr;27(4):616-619
pubmed: 33619368
Nat Rev Clin Oncol. 2016 Jan;13(1):25-40
pubmed: 26525683
Sci Rep. 2016 May 04;6:24799
pubmed: 27142790
Nature. 2016 Sep 15;537(7620):363-368
pubmed: 27595334
Sci Transl Med. 2020 Jan 8;12(525):
pubmed: 31915305
Cancer Cell. 2017 Oct 9;32(4):506-519.e5
pubmed: 29017060
J Cancer Res Clin Oncol. 2016 Oct;142(10):2141-58
pubmed: 27530445